Tysabri and Progressive Multifocal Leukoencephalopathy: Understanding the Diagnosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specific Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the connection to progressive multifocal leukoencephalopathy (PML) is critical. This condition, caused by reactivation of the JC virus, requires early recognition for better outcomes. Building on established medical guidelines, this page provides a clear overview of PML diagnosis, risk stratification, and current safety monitoring recommendations.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the condition has been documented in patients receiving Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, healthcare professionals must monitor patients for any new sign or symptom suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically involves brain imaging and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow reactivation of latent JCV, leading to PML. The timeline between exposure and documented harm can vary, with PML cases reported after a few months to several years of Tysabri treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Regarding the adequacy of warnings, the boxed warning explicitly states that Tysabri increases the risk of PML and that the condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information also requires that patients be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks, and complete and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are required to evaluate patients at specified intervals—three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri-Related PML Claims in California

For affected patients in California, settlement-related considerations involve the statute of limitations for filing claims. In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For claims involving latent diseases such as PML, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused the harm. Given that PML can develop after prolonged Tysabri use, the timeline between exposure and documented harm is critical. Patients diagnosed with PML after Tysabri treatment should promptly seek legal counsel to assess their specific circumstances, as delays could bar recovery. Settlement amounts may vary based on factors such as severity of disability, medical expenses, lost earnings, and the strength of evidence linking Tysabri to the patient's PML. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and monitoring requirements outlined in its prescribing information. Patients in California who develop PML after Tysabri use should be aware of the statute of limitations and seek timely legal advice to preserve their rights. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For latent diseases like PML, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused the harm. It is crucial to seek legal advice promptly to avoid missing the deadline.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for developing PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.